Xi Zong Sun

Xi Zong Sun


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in ACS Omega
Verified
Journal Article
Open access
XZXiangpei Zhao
Xiangpei Zhao
ZLZhaoyang Long
Zhaoyang Long
HZHua Zhong
Hua Zhong
RLRongping Lu
Rongping Lu
JWJuan Wei
Juan Wei
XSXi Zong Sun
Xi Zong Sun
Objectives: To examine the anti-inflammatory properties and underlying mechanisms of Tongfeng Li'an Granules (TFLA), a traditional medicine, in acute gouty arthritis using a rat model. Materials and Methods: We identified 55 major compounds in TFLA via ultrahigh-performance liquid chromatography connected to quadrupole time-of-flight mass spectrometry (UPLC-TQF-MS/MS). Databases were employed for the prediction of potential targets, followed by PPI network construction as well as GO and KEGG analyses. After network-pharmacology-based analysis, a rat gouty arthritis model was used to validate the anti-inflammatory mechanism of TFLA. Results: UPLC-TQF-MS/MS and network pharmacology analyses revealed 55 active ingredients and 160 targets of TFLA associated with gouty arthritis, forming an ingredient-target-disease network. The PPI network identified 20 core targets, including TLR2, TLR4, IL6, NF kappa B, etc. Functional enrichment analyses highlighted the Toll-like receptor signaling pathway as significantly enriched by multiple targets, validated in in vivo experiments. Animal experiments demonstrated that TFLA improved pathological changes in gouty joint synovium, with decreased ankle joint circumference, serum IL6, IL10, and TNF alpha levels, as well as reduced protein and mRNA expression of NLRP3, TLR2, and TLR4 in ankle joint synovial tissue observed in the middle- and high-dose TFLA and positive control groups compared to the model group (p < 0.05). Conclusion: This research elucidated the pharmacological mechanisms of TFLA against gouty arthritis, implicating various ingredients, targets, and signaling pathways. Animal experiments confirmed TFLA's efficacy in alleviating inflammation in acute gouty arthritis by modulating Toll-like receptor signaling and NLRP3 expression.

1 August 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
KCKuikui Chen
Kuikui Chen
JLJie Liang
Jie Liang
YTYong Tan
Yong Tan
YLYaohua Li
Yaohua Li
XPXiaojiao Pan
Xiaojiao Pan
XSXi Zong Sun
Xi Zong Sun
Background: Isodon lophanthoides, a core botanical drug in Yao ethnomedicine, has traditionally been used to treat jaundice-type hepatitis and cholecystitis. However, its therapeutic potential and mechanisms against liver fibrosis remain largely unexplored.Methods: The metabolites of I. lophanthoides water extract (ILW) were characterized by ultra-performance liquid chromatography (UPLC) and UPLC coupled with quadrupole time-of-flight mass spectrometry (Q-TOF/MS). A carbon tetrachloride (CCl4)-induced liver fibrosis mouse model was employed to evaluate the anti-fibrotic effects of ILW. An integrated multi-omics approach encompassing transcriptomics, proteomics, and metabolomics was used to elucidate the underlying mechanisms, further supported by Western blotting, targeted metabolite quantification, and enzyme-linked immunosorbent assay (ELISA).Results: Thirty-two metabolites were identified in ILW. Among them, the concentrations of caffeic acid, rosmarinic acid, schaftoside, and isoschaftoside were determined to be 1.10, 5.13, 0.12, and 0.18 mg·g-1, respectively. ILW treatment significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), procollagen type III (PC-III), collagen type IV (COL-IV), laminin (LN), and hyaluronic acid (HA) in liver fibrotic mice. Histopathological analyses showed that ILW significantly alleviated liver inflammation, collagen deposition, and fibrosis. Multi-omics analysis revealed that ILW’s anti-fibrotic effects are linked to modulation of purine metabolism and inhibition of the nuclear factor kappa-B (NF-κB) signaling pathway. High-dose ILW lowered hepatic levels of adenine, adenosine monophosphate (AMP), and inosine monophosphate (IMP), while increasing adenosine, hypoxanthine, and N6-methyladenosine (m6A). Furthermore, high-dose and medium-dose ILW downregulated key NF-κB-related proteins, including toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), phosphorylated NF-κB, transforming growth factor beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β).Conclusion: ILW exerts protective effects against liver fibrosis by attenuating inflammation, fibrosis, and liver damage through modulation metabolism modulation and NF-κB pathway inhibition. These findings provide a scientific basis for the traditional use of I. lophanthoides in liver-related disorders.

20 October 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HGHuiqiong Guo
Huiqiong Guo
JLJing Liang
Jing Liang
HHHaili Huang
Haili Huang
ZZZimo Zhang
Zimo Zhang
XHXin Huang
Xin Huang
YHYinghong Huang
Yinghong Huang
Introduction: Psoralen (PSO) is an anticancer agent with a potential role in breast cancer management. Its clinical application, however, is significantly limited by poor aqueous solubility and low bioavailability. Therefore, the development of advanced PSO delivery systems is essential to enhance its therapeutic potential. Methods: In this study, a novel nano-delivery platform was constructed by encapsulating PSO into zein nanoparticles (NPs) followed by surface modification with fucoidan (Fu), yielding PSO-Z/F NPs. Results: Successful surface modification was confirmed by a reversal in ζ potential from positive values to −24.8 ± 0.02 mV, an increase in particle size to 129.23 ± 0.18 nm, characteristic changes in sulfate-related Fourier transform infrared spectroscopy (FTIR) bands, and the appearance of an S 2p signal in X-ray photoelectron spectroscopy (XPS). The PSO-Z/F NPs exhibited a uniform spherical morphology, with an encapsulation efficiency of 73.13 ± 0.98% and a drug-loading capacity of 5.40 ± 0.35%. Cellular uptake of PSO-Z/F NPs was 1.6-fold higher than that of uncoated PSO-Z NPs ( P < 0.05). In vitro , PSO-Z/F NPs significantly suppressed the proliferation, migration, and invasion of 4T1 breast cancer cells. Specifically, wound closure rate decreased from 29.13 ± 3.33 % in the control group to 5.02 ± 2.86% ( P < 0.001). Compared with the PSO group, the number of migrated cells decreased from 220 ± 33 to 146 ± 20 ( P < 0.01), while that of invaded cells decreased from 144 ± 21 to 90 ± 8 ( P < 0.05). Moreover, PSO-Z/F NPs increased the total apoptosis rate from 6.45% in the control group to 17.98% ( P < 0.01). In addition, hemolysis assays showed reduced hemolytic activity, while serum-incubation studies confirmed improved colloidal stability, as evidenced by minimal changes in particle size and PDI over 7 days. Notably, in vivo and ex vivo fluorescence analysis of tumors and major organs in 4T1 tumor-bearing mice showed efficient tumor accumulation of PSO-Z/F NPs, and pharmacodynamic studies indicated enhanced tumor growth inhibition with an acceptable biosafety profile. Discussion: Overall, PSO-Z/F NPs may provide a potential nanoparticle-based delivery strategy for improving the therapeutic application of psoralen in breast cancer.